Psychedelic Legalization Guide

Measure 109 (2020) created the first U.S. regulated psilocybin services system; service centers began serving clients in mid-2023. By early 2026 roughly 22-23 service centers operated (of ~35 licensed) with nearly 400 active facilitators and an estimated 15,000-16,000 clients served, though the program faces budget shortfalls and local bans in most counties. Measure 110 (2020) also decriminalized personal drug possession, but that broader policy was largely rolled back in 2024.

Proposition 122 / Natural Medicine Health Act (2022) decriminalized personal use of psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote) for adults 21+ and created a regulated 'healing center' model; first facilitator licenses were issued in January 2025 and first healing-center licenses on March 24, 2025. In 2025 the state moved toward adding ibogaine as a natural medicine and established an ibogaine research pilot (up to five sites).

The Medical Psilocybin Act (SB 219) was signed April 7, 2025 (effective June 20, 2025) — the first state to legalize psilocybin therapy through legislation rather than a ballot measure. Qualifying conditions include treatment-resistant depression, PTSD, substance use disorders, and end-of-life care; the Department of Health targets first licensed patient sessions by the end of December 2026. It appropriated $1M to DOH and $500K for UNM research.

Gov. Greg Abbott signed SB 2308 in June 2025, committing $50M to a consortium conducting FDA clinical trials of ibogaine for addiction and brain trauma — the largest publicly funded psychedelic research initiative worldwide. The state retains rights to at least 20% of any resulting successful drug, with a portion earmarked for veterans. Texas also passed a 2021 psilocybin study law (HB 1802).

Gov. Phil Murphy signed the Psilocybin Behavioral Health Access and Services Act on January 20, 2026, creating a state-run, hospital-based psilocybin research pilot at three hospitals with $6M in funding for conditions like PTSD and treatment-resistant depression, and reducing possession penalties. It does not create open public access.

SB 266 (2024) created a three-year pilot allowing licensed providers at University of Utah Health and Intermountain Health to administer psilocybin and MDMA in controlled settings; there is no general decriminalization. It follows an HB 167 (2022) task force.

Connecticut authorized a psilocybin/MDMA therapy pilot study in 2022 and appropriated modest research funding; personal possession remains a criminal offense.

Arizona funds a state psilocybin research grants program. Some aggregator sources describe personal-use decriminalization contexts for natural psychedelics, but that scope should be confirmed against primary sources before relying on it; MDMA and LSD are not included.

SB 58, which would have decriminalized personal possession of certain plant-based psychedelics, passed the legislature but was vetoed by Gov. Newsom in October 2023. Several cities (Oakland, Santa Cruz, and others) have deprioritized enforcement.

Question 4 (November 2024), which would have legalized regulated therapeutic access to five natural psychedelics plus home cultivation, was defeated roughly 56%-43% (its home-grow provisions were cited as a factor). Several cities (Somerville, Cambridge, Northampton) had previously decriminalized.

SB 5263 (2023) funded a psilocybin advisory work group and pilot studies; Tacoma decriminalized natural psychedelics (January 28, 2025) and Seattle had deprioritized earlier. There is no statewide legal-access system yet.

Ann Arbor (September 2020), Detroit (Proposal E, November 2021), Ferndale (February 2023) and other cities made entheogenic plant/fungi enforcement the lowest police priority; there is no statewide reform.

Initiative 81 (Entheogenic Plant and Fungus Policy Act) was approved by roughly 76% of voters in November 2020 and took effect March 16, 2021, making enforcement against psilocybin mushrooms and entheogenic plants the lowest police priority.

SB 242 (2023) created a 15-member Psychedelic Medicines Working Group under HHS to study psilocybin/psilocin and develop a plan for safe therapeutic access; subsequent legalization bills have been introduced but not enacted.

Sen. Rachel Ventura's CURE Act (Compassionate Use and Research of Entheogens Act) would legalize supervised psilocybin use at licensed service centers and create a Psilocybin Advisory Board; it is advancing but not yet enacted as of mid-2026.

The Task Force on Responsible Use of Natural Psychedelic Substances (created 2024) recommended in November 2025 that lawmakers decriminalize and move toward clinical and adult use of psilocybin, DMT, and mescaline.

The Psychedelic Medicine Task Force (established 2023) recommended a state-regulated therapeutic psilocybin program, removing criminal penalties for personal psilocybin use, and funding research into MDMA, psilocybin, and LSD.